文献速递食管胃疾病与幽门螺杆菌炎症性肠病

根除幽门螺杆菌治疗对自身免疫性疾病(包括炎症性肠病)发病率的影响

Effects of Anti-Helicobacter pylori Therapy on Incidence of Autoimmune Diseases, Including Inflammatory Bowel Diseases.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-12-20

基于台湾全民健康保险研究数据库,纳入79,181例18岁以下无自身免疫病或炎症性肠病(IBD)既往诊断的患儿,比较消化性溃疡病(PUD)接受幽门螺杆菌治疗、PUD未接受幽门螺杆菌治疗、使用头孢菌素治疗的尿路感染(UTI)及无PUD对照组的自身免疫病或IBD风险。结果显示PUD+幽门螺杆菌治疗组自身免疫病或IBD的校正风险比最高(aHR 2.36),高于PUD未治疗组(aHR 1.91)和UTI组(aHR 1.71)(P < .001)。作者结论认为幽门螺杆菌治疗与自身免疫病(包括IBD)风险显著增加相关。

要点

  • 纳入79,181例18岁以下无自身免疫病或IBD既往诊断的患儿,随访自身免疫病或IBD发生。
  • PUD+幽门螺杆菌治疗组自身免疫病或IBD的aHR为2.36,高于PUD未治疗组(1.91)和UTI组(1.71)(P < .001)。
  • PUD+幽门螺杆菌治疗组死亡率小幅但显著增加(aHR 1.11;P = .001)。

核心结论

  • 作者结论认为,幽门螺杆菌治疗与自身免疫病(包括IBD)风险显著增加相关。

研究设计与样本

  • 按年龄、性别、保险和Charlson合并症指数评分匹配,分为PUD接受幽门螺杆菌治疗组、PUD未接受幽门螺杆菌治疗组、使用头孢菌素治疗的UTI组及无PUD对照组。

主要发现

  • PUD+幽门螺杆菌治疗组自身免疫病或IBD的aHR为2.36,高于PUD未治疗组(aHR 1.91)和UTI组(aHR 1.71)(P < .001)。
  • PUD+幽门螺杆菌治疗组自身免疫病风险高于UTI组(P < .001),提示风险增加不完全由抗生素治疗本身解释。
  • PUD+幽门螺杆菌治疗组死亡率小幅但显著增加(aHR 1.11;P = .001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Helicobacter pylori induces immune tolerance and is associated with a lower risk for immune-mediated disorders, such as autoimmune and inflammatory bowel diseases (IBD). We aimed to determine the effects of treatment for H pylori infection on the incidence of autoimmune disease and IBD. METHODS: We collected data from the National Health Insurance Research Database in Taiwan on patients younger than 18 years old without a prior diagnosis of autoimmune disease or IBD. Patients with peptic ulcer disease (PUD) with treatment of H pylori infection (PUD+HPRx), PUD without H pylori treatment (PUD-HPRx), a urinary tract infection (UTI) treated with cephalosporin, or without PUD (controls) were matched for age, sex, insurance, and Charlson's comorbidity index score. RESULTS: Of the 1 million patients we collected data from in 2005, we included 79,181 patients in the study. We compared the effects of treatment for H pylori infection on the risk of autoimmunity or IBD and found that PUD+HPRx has the highest adjusted hazard risk (aHR) for autoimmunity or IBD (aHR, 2.36), compared to PUD-HPRx (aHR, 1.91) or UTI (aHRs, 1.71) (P < .001). The increased risk of autoimmune disease was not completely accounted for by antibiotic therapy alone, because PUD+HPRx had a higher aHR than UTI (P < .001). A small but significant increase in mortality was observed in the PUD+HPRx cohort (aHR, 1.11; P = .001). CONCLUSION: In an analysis of data from the National Health Insurance Research Database in Taiwan, we found that treatment for H pylori infection is associated with a significant increase in the risk for autoimmune disease, including IBD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lin KD, Chiu GF, Waljee AK, et al. Effects of Anti-Helicobacter pylori Therapy on Incidence of Autoimmune Diseases, Including Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2018. PMID: 30580094. doi:10.1016/j.cgh.2018.12.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。